Table S1—Change From Baseline for Percentage of Sleep Stages per TST (FAS).

Mean (SD), % of Sleep Stage per TST	PBO (N = 208)	ZOL (N = 263)	LEM5 (N = 266)	LEM10 (N = 269)
Nights 1/2[a]				
Total NREM	−0.3 (4.5)	1.1 (6.1)	−1.8 (5.0)	−4.2 (5.3)
N1	0.0 (3.5)	−1.6 (4.2)	−0.8 (4.0)	−1.8 (4.8)
N2	−0.2 (6.8)	2.5 (7.1)	0.0 (6.2)	−1.2 (7.3)
N3	−0.1 (5.5)	−0.1 (5.4)	−1.0 (5.6)	−1.3 (4.7)
Stage R	0.3 (4.5)	−1.1 (6.1)	1.8 (5.0)	4.2 (5.3)
Nights 29/30[b]				
Total NREM	0.4 (5.3)	0.8 (5.6)	−0.7 (5.4)	−2.3 (5.5)
N1	−0.5 (3.9)	−1.1 (4.2)	−0.1 (3.6)	−0.4 (6.1)
N2	1.3 (7.5)	3.7 (7.7)	1.1 (6.4)	−0.2 (7.8)
N3	−0.3 (6.1)	−1.8 (5.7)	−1.7 (5.4)	−1.7 (5.5)
Stage R	−0.4 (5.3)	−0.8 (5.6)	0.7 (5.4)	2.3 (5.5)

Values are presented as mean (SD), %.

[a]PBO, n = 208; ZOL, n = 262; LEM5, n = 266; LEM10, n = 269. [b]PBO, n = 200; ZOL, n = 250; LEM5, n = 260; LEM10, n = 260. Percentage of sleep stages are per TST. FAS = full analysis set, LEM5 = lemborexant 5 mg, LEM10 = lemborexant 10 mg, NREM = nonrapid eye movement sleep, Stage R= rapid eye movement, PBO = placebo, SD = standard deviation, TST = total sleep time, ZOL = zolpidem tartrate extended release 6.25 mg.